Clinical remission following treatment with tumour necrosis factor-alpha antagonists is not accompanied by changes in asymmetric dimethylarginine in patients with rheumatoid arthritis

► Endothelial dysfunction contributes to the enhanced cardiovascular morbidity in RA. ► ADMA represents a novel biomarker of endothelial dysfunction. ► Despite clinical improvement, anti-TNFα treatment does not affect ADMA in RA.